KHẢO SÁT TỶ LỆ SỬ DỤNG CÁC NHÓM THUỐC NỀN TẢNG TRONG ĐIỀU TRỊ BỆNH NHÂN SUY TIM PHÂN SUẤT TỐNG MÁU GIẢM TẠI BỆNH VIỆN ĐA KHOA THÀNH PHỐ CẦN THƠ

Abstract

Background: Heart failure with reduced ejection fraction (HFrEF) has a high morbidity and mortality rate. Correct treatment according to the newly updated guidelines significantly improves hospitalization and mortality rates. Adequate and accurate application of heart failure treatment protocols at provincial hospitals has not yet been studied. Objective: The study aims to survey the utilization rates of guideline-recommended foundational drug classes in the treatment of HFrEF according to the 2021 European Society of Cardiology (ESC) guidelines. Subjects and Methods: Patients with HFrEF visited the Cardiology Department at Can Tho City General Hospital from December 2023 to April 2024. The study employed a cross-sectional descriptive method. Results: The study enrolled 72 patients with HFrEF, with an average age of 67.14 ± 12.1 years, of which 52.8% were male. The most common comorbidities were hypertension (93.1%), coronary artery disease (79.2%), and dyslipidemia (79.2%). The primary cause of HFrEF in the study sample was coronary artery disease (75%). The proportions of patients using 1, 2, 3, or all 4 foundational drug classes were 31.9%, 56.9%, 5.6%, and 0%, respectively, with 94.4% of patients being treated with at least one of the four drug classes. Specifically, the usage rates of the drug classes were: Renin-Angiotensin-Aldosterone system inhibitors (RASi) at 88.9%, aldosterone antagonists at 61.1%, beta-blockers at 12.5%, and sodium-glucose co-transporter-2 inhibitors (SGLT2i) at 1.4%. Conclusion: Most HFrEF patients in our study were treated with either monotherapy or a combination of two drug classes, while the rates of patients receiving therapy with three or all four foundational drug classes remained low. RASi was the most commonly used drug class, whereas the usage rates of beta-blockers and SGLT2i were very low.